To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults

Inclusion Criteria: * Healthy adult male volunteers aged 19 to 45 years * Subjects who have over 50kg and BMI more than 18.5kg/m2 and less than 29.9kg/m2 * Males must be agree to practice a medically acceptable method\* of birth control and will not donate sperm during the study. * Subjects who provided written informed consent to participate in this study and voluntarily taken part in during the entire study period Exclusion Criteria: * Subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease * Subject with symptoms of acute disease within 28days prior to study medication dosing * Medical history or evidence that can affect absorption, distribution, metabolism and excretion of a given drug * Drugs or other drugs (aspirin, antibiotics, etc.) that contain the following drug categories or components of the same strain have an overactive or clinically significant history of hypersensitivity: * Subject with a history of drug abuse or urinalysis positive * Subject with clinically significant active chronic disease * Subject with genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption. * Genetic myopathic disorder or related family history * Positive test results for HBs Ab, HCV Ab, Anti HIV(AIDS), RPR Ab * Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug) * Subject who cannot take standard meal in hospitalization * Present history of hypothyroidism or clinically significant assay * Subjects who donated whole blood or partial blood within 2 or 1 month, respectively, prior to the first administration. * Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 30days prior to study medication dosing * Smokers whose average daily smoking amount exceeds 10 cigarettes per day within 3 months before the first dosing day and those who can't quit from 48 hours before dosing to the time of the last blood sampling. * Subjects who judged ineligible by the investigator